Overview
EVGN market data
Price History
EVGN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.08 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.32 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.37 – $1.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $6.5 · P/B 3.52 · P/S 5.26.
Company news
Evogene Announces Strategic Collaboration With ELIO To Discover And Develop Small-Molecule Oral Inhibitors To Treat Hyperlipidemia And Cardiovascular DiseasesBenzinga · Jul 22, 2026, 12:08 PM
Evogene's AgPlenus Subsidiary Introduces Antifungal Potency PredictorBenzinga · Jul 15, 2026, 11:33 AM
Evogene, Tel Aviv University's Blavatnik Center For Drug Discovery Announce Joint Initiative To Accelerate AI-Driven Small-Molecule Drug DiscoveryBenzinga · Jul 8, 2026, 11:15 AM
Evogene Completes Milestone In Second Collab With Google Cloud, Integration Of Agentic Computational Systems Within Its ChemPass AI PlatformBenzinga · Jun 24, 2026, 12:15 PM
Full Transcript: Evogene Q1 2026 Earnings CallBenzinga · Jun 11, 2026, 10:51 AM
Evogene shares are trading lower. The company announced completion of the first-in-human Phase 1 clinical study of BMC128 in combination with Nivolumab in patients with advanced solid tumors.Benzinga · Jun 2, 2026, 2:29 PM
Evogene Completes First-In-Human Phase 1 Clinical Study Of BMC128, Rationally-Designed Live Bacterial Product Developed By Its Subsidiary, Biomica, In Combination With Nivolumab In Patients With Advanced Solid TumorsBenzinga · Jun 2, 2026, 11:11 AM
Evogene Reports Early Results for Cancer Therapy Study, Experimental Treatment Meets Safety Goal in First Human TrialBenzinga · Jun 2, 2026, 11:06 AM
Evogene Files Secondary Offering Of 2,446,707 Shares By Selling ShareholderBenzinga · May 20, 2026, 1:00 PM
Earnings Scheduled For May 20, 2026Benzinga · May 20, 2026, 11:15 AM